Johns Hopkins Study Finds Anti-Parasitic Drug Slows Pancreatic Cancer in Mice

As the third-most lethal cancer in the United States, with only a 1% five-year survival rate for people with its most aggressive form, pancreatic cancer has long been a target of researchers who search for ways to slow or stop its growth and spread.

Now, a team of Johns Hopkins Medicine researchers have found that an anti-parasitic drug prevents pancreatic cancer's initiation, progression and metastasis in genetically engineered mice.